(Q35185775)

7 August 2017

1 reference

title

AE-941, a multifunctional antiangiogenic compound: trials in renal cell carcinoma (English)

1 reference

7 August 2017

main subject

angiogenesis inhibitor

1 reference

Ronald M Bukowski

1

1 reference

7 August 2017

language of work or name

English

0 references

publication date

1 August 2003

1 reference

Expert Opinion on Investigational Drugs

7 August 2017

published in

1 reference

7 August 2017

volume

12

1 reference

7 August 2017

issue

8

1 reference

7 August 2017

page(s)

1403-1411

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.8.1403

7 August 2017

1 reference

Treatment outcome and survival associated with metastatic renal cell carcinoma of non-clear-cell histology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.8.1403

Evolving classification of renal cell neoplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.8.1403

Molecular basis of the VHL hereditary cancer syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.8.1403

The von Hippel-Lindau tumor suppressor protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.8.1403

Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.8.1403

A phase I trial of weekly gemcitabine and subcutaneous interferon alpha in patients with refractory renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.8.1403

Spontaneous regression of metastases of renal cancer: A report of two cases including the first recorded regression following irradiation of a dominant metastasis and review of the world literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.8.1403

Interferon gamma-1b compared with placebo in metastatic renal-cell carcinoma. Canadian Urologic Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.8.1403

Disease-associated bias in T helper type 1 (Th1)/Th2 CD4(+) T cell responses against MAGE-6 in HLA-DRB10401(+) patients with renal cell carcinoma or melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.8.1403

Natural history and therapy of metastatic renal cell carcinoma: the role of interleukin-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.8.1403

Interferon-alpha in malignant and viral diseases. A review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.8.1403

Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.8.1403

Inhibition of tumor angiogenesis mediated by cartilage

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.8.1403

Shark Cartilage Contains Inhibitors of Tumor Angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.8.1403

Regression of blood vessels precedes cartilage differentiation during chick limb development

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.8.1403

Identification of an Inhibitor of Neovascularization from Cartilage

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.8.1403

Isolation and characterization of an inhibitor of neovascularization from scapular chondrocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.8.1403

Matrix metalloproteinases in angiogenesis: a moving target for therapeutic intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.8.1403

Vascular endothelial growth factor, a potent and selective angiogenic agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.8.1403

Phase I/II Trial of the Safety and Efficacy of AE-941 (Neovastat®) in the Treatment of Non–Small-Cell Lung Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.8.1403

10.1517/13543784.12.8.1403

21 January 2018

Identifiers

DOI

1 reference

7 August 2017

1 reference